MMRGlobal lays IP groundwork in Asia
HONG KONG – Most of Favrille Inc.’s market value vanished in 2008 after the firm said it would cease development of its active immunotherapy Specifid, which missed its primary endpoint in a pivotal phase III study in non-Hodgkin’s lymphoma. Almost a year later, San Diego-based Favrille merged with MyMedical-Records.com. The company once best known for providing health care IT services is just now stepping up its push into the biotechnology space in Asia.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST